BALTIMORE, Nov. 20 /PRNewswire/ -- Lentigen Corporation, a biopharmaceutical company focused on the discovery and development of novel biologics based on its proprietary LentiMax(TM) platform, announced today the appointment of Adam L. Sachs to the newly created position of President, Commercial Operations.
“Adam is joining Lentigen at an exciting time,” remarked Dr. Boro Dropulic, Founder and CEO of Lentigen. “We are completing development of our lentiviral platform, and Adam will oversee our product commercialization efforts.”
Adam Sachs has worked in the biotechnology sector for more than 15 years. He has held senior management positions for three market-leading life science research products companies. As Director of Manufacturing for Life Technologies (now Invitrogen), Mr. Sachs oversaw all molecular biology product operations. He also led the successful relocation and integration of Custom Primers, Inc., a 24/7 just-in-time custom oligonucleotide manufacturing acquisition. As Director of Manufacturing for QIAGEN Sciences, Mr. Sachs was responsible for starting up its East Coast Operon custom oligonucleotide manufacturing facility, and he made major contributions to Operon’s West Coast, German and Japanese operations. Most recently, Mr. Sachs served as Vice President of Operations for OriGene Technologies, where he focused on designing and implementing the infrastructure required for product and service commercialization and growth.
In addition to his expertise in operations and logistics, Mr. Sachs has extensive experience in sales management, business development, and strategic planning, and he also has an impressive track record of personnel and team development. Mr. Sachs holds a B.S. in Chemistry from the University of Michigan and an M.S.E. in Chemical Engineering from the University of California, San Diego.
“I am thrilled to be joining the Lentigen team, particularly at this stage in their evolution,” commented Sachs. “I am very impressed with the Lentigen management team, the technology platform, and most importantly, the company’s mission. I look forward to contributing to Lentigen’s growth in the years ahead.”
About Lentigen Corporation
Lentigen Corporation is a biopharmaceutical company focused on the manufacture and development of novel biologics through the use of lentiviral vectors (LVs). Lentigen’s key mission is to further development of its proprietary therapeutic pipeline, led by the company’s virus-like particle (VLP) vaccine program for influenza infection. LentiMax(TM), Lentigen’s proprietary lentiviral vector platform, has led to all of Lentigen’s current programs, and ongoing activities. For further information, visit www.Lentigen.com.
Contacts: Media Contact: Gregory Tiberend Richard Lewis Communications, Inc. 212-827-0020 gtiberend@rlcinc.com Investor Contact: Tara Spiess TS Communications Group, LLC 914-921-5900 spiess@biotechirpr.com
Lentigen Corporation
CONTACT: Media Contact - Gregory Tiberend, Richard Lewis Communications,Inc., +1-212-827-0020, gtiberend@rlcinc.com; Investor Contact - TaraSpiess, TS Communications Group, LLC, +1-914-921-5900,spiess@biotechirpr.com
Web site: http://www.Lentigen.com/
